CAMBRIDGE, Mass., April 11, 2017 /PRNewswire/ -- 1CellBiO Inc announced today a research collaboration with UCB to validateand deploy the inDrop™ high throughput single cell RNA sequencing platform in order to better understand the cellular composition of complex tissues, and to assess cellular responses to novel and existing therapies."We are pleased to enter
About 1CellBiO Inc.The company is a leader in products enabling high throughput, single cell biology, including inDrop™ for high throughput single cell RNA sequencing. Learn more at www.1cell-bio.com.
About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology and neurology. With more than 7500 people in approximately 40 countries, the company generated revenue of €4.2 billion in 2016. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/1cellbio-inc-announces-collaboration-agreement-with-ucb-300437670.html
SOURCE 1CellBiO Inc.
Subscribe to our Free Newsletters!